ATEZOLIZUMAB

Brand name:

• Tecentriq®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Roche Products Pty Ltd

Condition/indication:
(therapeutic use)

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) Stage IV (metastatic) NSCLC Extensive-stage small cell lung cancer Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma Resected early stage (Stage II to IIIA) NSCLC

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (Category 4)

Comment:

--

Other PBAC consideration:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

15/04/2024

Lodgement of required documentation:

23/04/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 07/05/2024

Status:

Finalised

Government processes:

Commenced on 24/05/2024

Medicine listed on the PBS:

01/08/2024 (see PBS schedule)